BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 32386721)

  • 1. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
    Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
    Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
    Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Lockman S; Brummel SS; Ziemba L; Stranix-Chibanda L; McCarthy K; Coletti A; Jean-Philippe P; Johnston B; Krotje C; Fairlie L; Hoffman RM; Sax PE; Moyo S; Chakhtoura N; Stringer JS; Masheto G; Korutaro V; Cassim H; Mmbaga BT; João E; Hanley S; Purdue L; Holmes LB; Momper JD; Shapiro RL; Thoofer NK; Rooney JF; Frenkel LM; Amico KR; Chinula L; Currier J;
    Lancet; 2021 Apr; 397(10281):1276-1292. PubMed ID: 33812487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
    Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
    PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
    Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
    Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
    Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
    Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
    Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
    Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
    Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
    Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
    Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial.
    Dooley KE; Savic R; Gupte A; Marzinke MA; Zhang N; Edward VA; Wolf L; Sebe M; Likoti M; Fyvie MJ; Shibambo I; Beattie T; Chaisson RE; Churchyard GJ;
    Lancet HIV; 2020 Jun; 7(6):e401-e409. PubMed ID: 32240629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
    Amuge P; Lugemwa A; Wynne B; Mujuru HA; Violari A; Kityo CM; Archary M; Variava E; White E; Turner RM; Shakeshaft C; Ali S; Nathoo KJ; Atwine L; Liberty A; Bbuye D; Kaudha E; Mngqibisa R; Mosala M; Mumbiro V; Nanduudu A; Ankunda R; Maseko L; Kekitiinwa AR; Giaquinto C; Rojo P; Gibb DM; Turkova A; Ford D;
    Lancet HIV; 2022 Sep; 9(9):e638-e648. PubMed ID: 36055295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
    Facha W; Tadesse T; Wolka E; Astatkie A
    PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.
    Davey S; Ajibola G; Maswabi K; Sakoi M; Bennett K; Hughes MD; Isaacson A; Diseko M; Zash R; Batlang O; Moyo S; Lockman S; Lichterfeld M; Kuritzkes DR; Makhema J; Shapiro R
    J Acquir Immune Defic Syndr; 2020 Jul; 84(3):235-241. PubMed ID: 32195745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
    Wijting I; Rokx C; Boucher C; van Kampen J; Pas S; de Vries-Sluijs T; Schurink C; Bax H; Derksen M; Andrinopoulou ER; van der Ende M; van Gorp E; Nouwen J; Verbon A; Bierman W; Rijnders B
    Lancet HIV; 2017 Dec; 4(12):e547-e554. PubMed ID: 29107562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
    Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
    Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
    Turkova A; White E; Mujuru HA; Kekitiinwa AR; Kityo CM; Violari A; Lugemwa A; Cressey TR; Musoke P; Variava E; Cotton MF; Archary M; Puthanakit T; Behuhuma O; Kobbe R; Welch SB; Bwakura-Dangarembizi M; Amuge P; Kaudha E; Barlow-Mosha L; Makumbi S; Ramsagar N; Ngampiyaskul C; Musoro G; Atwine L; Liberty A; Musiime V; Bbuye D; Ahimbisibwe GM; Chalermpantmetagul S; Ali S; Sarfati T; Wynne B; Shakeshaft C; Colbers A; Klein N; Bernays S; Saïdi Y; Coelho A; Grossele T; Compagnucci A; Giaquinto C; Rojo P; Ford D; Gibb DM;
    N Engl J Med; 2021 Dec; 385(27):2531-2543. PubMed ID: 34965338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.